NCT06596746 Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
| NCT ID | NCT06596746 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Casa di Cura San Raffaele Cassino |
| Condition | Neurodegenerative Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-09-09 |
| Primary Completion | 2034-09-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2024-09-09 with a primary completion date of 2034-09-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.
Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders * Patients with diagnosis of Parkinson's Disease * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank * Diagnosis of Movement Disorder not related to Parkinson's Disease * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; * Diagnosis of Essential Tremor * Willing to participate in the study, understand the procedures and sign the informed consent. * Patients affected by cognitive impairment (CI) and dementia * Diagnosis of probable: * Lewy Body Dementia * Alzheimer's Disease * Mild Cognitive Decline * Subjective memory complaints * Willing to participate in the study, understand the procedures and sign the informed consent. Exclusion Criteria: * There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06596746 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, studying Neurodegenerative Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06596746 currently recruiting?
Yes, NCT06596746 is actively recruiting participants. Contact the research team at maria.depandis@sanraffaele.it for enrollment information.
Where is the NCT06596746 trial being conducted?
This trial is being conducted at Cassino, Italy.
Who is sponsoring the NCT06596746 clinical trial?
NCT06596746 is sponsored by Casa di Cura San Raffaele Cassino. The trial plans to enroll 600 participants.